Marketing authorisation

European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of the marketing authorisation application (MAA) for Roclanda®

Marketing authorisation

Colin Kerr

Published: Monday, February 1, 2021

Aerie Pharmaceuticals has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of the marketing authorisation application (MAA) for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. “We are delighted that the CHMP has adopted a positive opinion for Roclanda®,” said Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer at Aerie. Roclanda is currently marketed as Rocklatan® in the United States and is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or hypertension. www.aeriepharma.com

Tags: aerie

Latest Articles

ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Supplement: ESCRS Clinical Trends Series: Presbyopia

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.